Jeffrey J. Tolin

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Halcyon on its $100 million Series C funding. Partner Derek Colla led the Cooley team advising Halcyon, an organization devoted to defeating ransomware through prevention and resilience by way of a proprietary technology that captures encryption keys, enabling organizations to recover from attacks in minutes without paying ransom.

Cooley advised Kpler, a fast-growing data and analytics firm on a mission to build one platform for global trade intelligence, on its acquisition of Spire Global’s maritime business for approximately $241 million.

Cooley advised Boldend, a top cyber automation company developing software solutions that enhance and scale cyber capabilities, on its acquisition by SIXGEN, a full-spectrum provider of cyber products, operations and solutions to the US national security and critical infrastructure sectors.

Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.